NZ598486A - Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy - Google Patents
Pharmaceutical compositions methods and kit for glucocorticoid replacement therapyInfo
- Publication number
- NZ598486A NZ598486A NZ598486A NZ59848605A NZ598486A NZ 598486 A NZ598486 A NZ 598486A NZ 598486 A NZ598486 A NZ 598486A NZ 59848605 A NZ59848605 A NZ 59848605A NZ 598486 A NZ598486 A NZ 598486A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dosage form
- present
- core
- hydroxypropylmethylcellulose
- coating material
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 title abstract 2
- 238000009256 replacement therapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 16
- 229960000890 hydrocortisone Drugs 0.000 abstract 8
- 238000013265 extended release Methods 0.000 abstract 5
- 239000011248 coating agent Substances 0.000 abstract 4
- 238000000576 coating method Methods 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920001800 Shellac Polymers 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 229920002494 Zein Polymers 0.000 abstract 1
- 239000004203 carnauba wax Substances 0.000 abstract 1
- 229940082483 carnauba wax Drugs 0.000 abstract 1
- 235000013869 carnauba wax Nutrition 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229960004667 ethyl cellulose Drugs 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 229940075507 glyceryl monostearate Drugs 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 abstract 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 abstract 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000004200 microcrystalline wax Substances 0.000 abstract 1
- 229940114937 microcrystalline wax Drugs 0.000 abstract 1
- 235000019808 microcrystalline wax Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000058 polyacrylate Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 239000004208 shellac Substances 0.000 abstract 1
- 229940113147 shellac Drugs 0.000 abstract 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 abstract 1
- 235000013874 shellac Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 229940083542 sodium Drugs 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229940033134 talc Drugs 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 229960005196 titanium dioxide Drugs 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
- 235000010215 titanium dioxide Nutrition 0.000 abstract 1
- 239000005019 zein Substances 0.000 abstract 1
- 229940093612 zein Drugs 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Disclosed is a coated tablet dosage form for delivery of glucocorticoid replacement therapy, comprising: an extended release (ER) tablet core and an immediate release (IR) coating surrounding said tablet core; said ER core comprising hydrocortisone (HC) and an ER excipient composition composed of: a combination of hydroxypropylmethylcellulose, microcrystalline cellulose and pregelatinized starch; colloidal silicon dioxide; and magnesium stearate, the amount of HC present in said ER core being 60% to 80% of the total amount of HC present in said dosage form; said IR coating material comprising HC and at least one coating material selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, acrylic polymers, ethylcellulose, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylalcohol, sodium carobxymethylcellulose, cellulose acetate, gelatin, methacrylic acid copolymer, polyethylene glycol, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, glyceryl monostearate, talc and zein, with the amount of HC present in said IR coating material being 20% to 40% of the total amount of HC present in said dosage form; and said dosage form being effective to deliver a daily dose of from about 1 to 80 mg of HC.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ598486A NZ598486A (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ58534004 | 2004-04-22 | ||
| NZ585340A NZ585340A (en) | 2004-04-22 | 2005-04-21 | Coated tablet composition comprising a coat for immediate release glucocorticoid and a core for extended release glucocorticoid for glucocorticoid replacement therapy |
| NZ598486A NZ598486A (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598486A true NZ598486A (en) | 2013-01-25 |
Family
ID=48570595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598486A NZ598486A (en) | 2004-04-22 | 2005-04-21 | Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ598486A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115308A (en) * | 2016-02-23 | 2017-09-01 | 天津金耀集团有限公司 | A kind of hydrocortisone two-phase sustained-release tablet composition |
-
2005
- 2005-04-21 NZ NZ598486A patent/NZ598486A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115308A (en) * | 2016-02-23 | 2017-09-01 | 天津金耀集团有限公司 | A kind of hydrocortisone two-phase sustained-release tablet composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1461015B1 (en) | Compositions containing both sedative and non-sedative antihistamines | |
| JP2017128614A5 (en) | ||
| TN2013000220A1 (en) | Orally disintegrating tablet | |
| CZ303495B6 (en) | Multiparticulate modified release composition, use thereof and solid oral dosage form | |
| JP2009523175A5 (en) | ||
| JP2010502762A5 (en) | ||
| ATE350040T1 (en) | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING A NON-STEROID ANTI-INFLAMMATORY ACT AND PROSTAGLANDIN | |
| NZ588499A (en) | Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating | |
| BRPI0317682B1 (en) | Modified release pharmaceutical composition in capsule form | |
| MX2007004987A (en) | New modified release tablet formulations for proton pump inhibitors. | |
| EA023971B1 (en) | Use of a composition comprising enterically coated cystamine or cysteamine for treating cystinosis and method of treating cystinosis | |
| WO2010140111A1 (en) | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant | |
| AU2018290287B2 (en) | Gastro-resistant controlled release oral dosage forms | |
| CA2570277A1 (en) | Medicament in a multilayer form | |
| US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms | |
| US7303761B2 (en) | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin | |
| WO2005055955B1 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
| AU736357B2 (en) | Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient | |
| TW201739455A (en) | Oral pharmaceutical compositions of nicotinamide | |
| NZ598486A (en) | Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy | |
| WO2006117803A2 (en) | Transmucosal drug delivery systems | |
| CA2433915A1 (en) | Improved controlled release oral dosage form | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| US9694007B2 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| MX2007008985A (en) | Controlled release compositions comprising an antipsychotic agent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 21 APR 2015 BY FB RICE Effective date: 20130506 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2016 BY FB RICE Effective date: 20150402 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2017 BY COMPUTER PACKAGES INC Effective date: 20160331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2018 BY COMPUTER PACKAGES INC Effective date: 20170331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2019 BY ANAQUA SERVICES Effective date: 20180320 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2020 BY ANAQUA SERVICES Effective date: 20190321 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2021 BY ANAQUA SERVICES Effective date: 20200318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2022 BY ANAQUA SERVICES Effective date: 20210323 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2023 BY ANAQUA SERVICES Effective date: 20220322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2024 BY ANAQUA SERVICES Effective date: 20230322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2025 BY ANAQUA SERVICES Effective date: 20240320 |